HYMS testimonial flipped

Endo180 Cancer

Translating our discoveries into improved cancer care.

The Challenge

Our challenge: translating our discoveries about the suppressor and promoter of invasive cell behaviour - Endo180 - into improved cancer care.

The Approach

Our approach:  we have developed a simple blood test with improved accuracy over other biomarkers - ENDOLEVELS - that can monitor the release of soluble Endo180 from glandular epithelial cells as they switch to an invasive phenotype during the onset of metastasis. A multi-modal bio-imaging probe - ENDOGLOWS - that can distinguish between the suppressor and promoter forms of Endo180 on the plasma membrane of glandular epithelial cells has also been developed to aid accurate diagnosis and precision surgery. The University of Hull spearheaded the Endo180 discoveries leading to these technological advances.

The Impact

Our impact: this multifaceted bench-to-bedside research program has been designed to establish Endo180-focussed care for cancer patients in the shortest possible time frame. This paradigm shift in clinical practice will also benefit people 'at risk' of developing Endo180-dependent tumours. The advances made will be expected to greatly improving the quality of life and extend the life expectancy of people with a range of primary and secondary cancer types, including prostate, breast, lung, pancreas, liver, bone and brain.

Start and expected completion date




The project is funded £500,000 by the Prostate Cancer UK & HEY Hospitals NHS Trust.

Contact us